$1.06
3.92% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Cue Biopharma, Inc. Stock price

$1.06
-0.42 28.38% 1M
-0.57 34.77% 6M
-1.58 59.85% YTD
-1.31 55.27% 1Y
-12.52 92.19% 3Y
-9.40 89.87% 5Y
-10.57 90.89% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.04 3.92%
ISIN
US22978P1066
Symbol
CUE
Sector
Industry

Key metrics

Market capitalization $67.15m
Enterprise Value $44.24m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 4.64
P/S ratio (TTM) P/S ratio 7.05
P/B ratio (TTM) P/B ratio 2.52
Revenue growth (TTM) Revenue growth 149.51%
Revenue (TTM) Revenue $9.53m
EBIT (operating result TTM) EBIT $-45.64m
Free Cash Flow (TTM) Free Cash Flow $-38.32m
Cash position $32.42m
EPS (TTM) EPS $-0.91
P/E forward negative
P/S forward 7.14
EV/Sales forward 4.70
Short interest 2.98%
Show more

Is Cue Biopharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Cue Biopharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Cue Biopharma, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Cue Biopharma, Inc. forecast:

Buy
100%

Financial data from Cue Biopharma, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
9.53 9.53
149% 149%
100%
- Direct Costs 3.45 3.45
9% 9%
36%
6.09 6.09
823% 823%
64%
- Selling and Administrative Expenses 8.38 8.38
16% 16%
88%
- Research and Development Expense 40 40
2% 2%
419%
-42 -42
16% 16%
-443%
- Depreciation and Amortization 3.45 3.45
9% 9%
36%
EBIT (Operating Income) EBIT -46 -46
14% 14%
-479%
Net Profit -45 -45
14% 14%
-468%

In millions USD.

Don't miss a Thing! We will send you all news about Cue Biopharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cue Biopharma, Inc. Stock News

Neutral
GlobeNewsWire
about 24 hours ago
BOSTON, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, announced today that it will take part in an unplugged fireside discussion at the Piper Sandler 36th Annual Healthc...
Neutral
GlobeNewsWire
12 days ago
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc.  (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024.
Neutral
GlobeNewsWire
12 days ago
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today announced that Daniel Baker, M.D., will join Cue Biopharma as interim chief development officer (CDO) effecti...
More Cue Biopharma, Inc. News

Company Profile

Cue Biopharma, Inc. is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.

Head office United States
CEO Daniel Passeri
Employees 53
Founded 2014
Website www.cuebiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today